Evidence map›Paper›PMID 35053559›Full record

ReviewCancers2022

Socio-Economic Inequalities in Lung Cancer Outcomes: An Overview of Systematic Reviews.

Daniel Redondo-Sánchez, Dafina Petrova, Miguel Rodríguez-Barranco, Pablo Fernández-Navarro, José Juan Jiménez-Moleón, Maria-José Sánchez

Abstract readReview
In one paragraph

Review in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Prediagnostic primary care consultations and imaging in emergency-diagnosed versus referred patients with lung cancer: a population-based linked data study.The British journal of general practice : the journal of the Royal College of General Practitioners · 2026
    Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Daniel Redondo-SánchezInstituto de Investigación Biosanitaria ibs.GRANADA, 18012 Granada, Spain.ORCID 0000-0001-9986-915X
Dafina PetrovaInstituto de Investigación Biosanitaria ibs.GRANADA, 18012 Granada, Spain.ORCID 0000-0002-0346-6776
Miguel Rodríguez-BarrancoInstituto de Investigación Biosanitaria ibs.GRANADA, 18012 Granada, Spain.ORCID 0000-0002-9972-9779
Pablo Fernández-NavarroCIBER of Epidemiology and Public Health (CIBERESP), 28029 Madrid, Spain.
José Juan Jiménez-MoleónInstituto de Investigación Biosanitaria ibs.GRANADA, 18012 Granada, Spain.ORCID 0000-0001-7917-6145
Maria-José SánchezInstituto de Investigación Biosanitaria ibs.GRANADA, 18012 Granada, Spain.ORCID 0000-0003-4817-0757

Funding

Asociación Española Contra el Cáncer PROYE20023SÁNCCancer Epidemiological Surveillance Subprogram (VICA) of the CIBERESP, Health Institute Carlos III, Madrid, Spain Not availableJuan de la Cierva Fellowship from the Ministry of Science and the National Research Agency of Spain MCIN/AEI, JC2019-039691-I
6 · The paper itself

Abstract

In the past decade, evidence has accumulated about socio-economic inequalities in very diverse lung cancer outcomes. To better understand the global effects of socio-economic factors in lung cancer, we conducted an overview of systematic reviews. Four databases were searched for systematic reviews reporting on the relationship between measures of socio-economic status (SES) (individual or area-based) and diverse lung cancer outcomes, including epidemiological indicators and diagnosis- and treatment-related variables. AMSTAR-2 was used to assess the quality of the selected systematic reviews. Eight systematic reviews based on 220 original studies and 8 different indicators were identified. Compared to people with a high SES, people with a lower SES appear to be more likely to develop and die from lung cancer. People with lower SES also have lower cancer survival, most likely due to the lower likelihood of receiving both traditional and next-generation treatments, higher rates of comorbidities, and the higher likelihood of being admitted as emergency. People with a lower SES are generally not diagnosed at later stages, but this may change after broader implementation of lung cancer screening, as early evidence suggests that there may be socio-economic inequalities in its use.

Indexed as

diagnosisdisparitieseducationincomeinequalitieslung cancersocio-economicsurvivaltreatment

Identifiers

PMID35053559
PMCPMC8773607

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.